Related Experiment Video
Updated: Jul 29, 2026

Analysis of Cardiomyocyte Development using Immunofluorescence in Embryonic Mouse Heart
Published on: March 26, 2015
Myofibrillar protein structure and assembly during idiopathic dilated cardiomyopathy
R J Levine1, J B Caulfield, P Norton
1Department of Neurobiology, MCP Hahnemann School of Medicine, Allegheny University of the Health Sciences, Philadelphia, USA.
Abstract:
A neutral protease, mekratin, active in human hearts at end stage idiopathic dilated cardiomyopathy (IDC), mediates the breakdown of cardiac myosin LC2. Myosin purified from IDC heart tissue forms unusually short synthetic thick filaments. Therefore, determination of filament length and mekratin distribution in IDC heart muscle were initiated. Native thick filaments were prepared directly from control and IDC tissues and analyzed. Also, paraffin-embedded tissue sections were stained with a fluorescently-labeled anti-protease antibody to establish its distribution in myocardial tissues. Control sections had only very weak, background levels of fluorescence whereas IDC sections stained intensely throughout, indicating a wide ranging distribution of the protease within the myocyte cytoplasm. SDS-PAGE revealed LC2 to be present in stoichiometric amounts in control but greatly reduced in IDC heart muscle. Native thick filaments from control myocardium were structurally stable. They had a median length of 1.65 microm with well-defined bare zones and displayed the 43 nm helical periodicity typical of the relaxed arrangement of myosin heads close to the filaments' shafts. In contrast, native IDC filaments were less stable, and had a median length of 0.9 microm. These filaments were highly disordered: they had no surface periodicity and myosin heads were positioned away from the filaments' shafts. The shorter, less stable, aperiodic thick filaments from IDC hearts appear to result from depletion of LC2 caused by increased activity of mekratin in the IDC myocardium.
Insights
A neutral protease, mekratin, breaks down cardiac myosin LC2 in end-stage idiopathic dilated cardiomyopathy (IDC) hearts. This protease activity leads to shorter, unstable cardiac myosin filaments, contributing to heart dysfunction.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- End-stage idiopathic dilated cardiomyopathy (IDC) is characterized by cardiac dysfunction.
- Cardiac myosin is crucial for heart muscle contraction.
- The role of specific proteases in IDC pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the role of the neutral protease mekratin in IDC.
- To determine the effect of mekratin on cardiac myosin thick filament structure and stability.
- To analyze the distribution of mekratin in IDC heart tissue.
Main Methods:
- Preparation and analysis of native thick filaments from control and IDC heart tissues.
- SDS-PAGE to assess cardiac myosin LC2 levels.
- Immunofluorescence staining of myocardial tissue sections to localize mekratin.
Main Results:
- Mekratin is highly active and widely distributed in IDC myocardium.
- Cardiac myosin LC2 is significantly reduced in IDC heart muscle.
- Native thick filaments from IDC hearts are shorter (0.9 µm vs. 1.65 µm), less stable, and aperiodic compared to controls.
Conclusions:
- Increased mekratin activity in IDC leads to cardiac myosin LC2 depletion.
- This depletion results in shorter, less stable, and disordered myosin thick filaments.
- Mekratin-mediated myosin degradation contributes to the pathophysiology of IDC.
Related Concept Videos
The Sarcomere
Each myosin...
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Myocarditis I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

